DISEASE SCANNER
Global Incurable Diseases Tracker
Chronic Graft-Versus-Host Disease (cGVHD)
Major complication of allogeneic stem cell transplantation where donor immune cells attack recipient tissues. Affects multiple organs including skin, eyes, mouth, liver, and lungs. Leading cause of non-relapse mortality post-transplant.
40.0K
15
Symptoms
Treatment Options
Risk Factors
Diagnostic Methods
- 1Biopsy of affected organ
- 2Pulmonary function tests
- 3Liver function tests
- 4Schirmer test
- 5Oral examination
- 6Skin examination
Prognosis
50% of allogeneic transplant recipients develop cGVHD. 5-year survival approximately 50-60%. Steroid-responsive disease has better prognosis (70% 5-year survival). Steroid-refractory disease has poor prognosis (30% 5-year survival). Major cause of late morbidity and mortality. Quality of life significantly affected.
Prevention
- HLA-matched donor
- T-cell depletion
- Methotrexate + tacrolimus prophylaxis
- Post-transplant cyclophosphamide
- Ursodiol prophylaxis
Research Status
First-line treatment with corticosteroids and calcineurin inhibitors. Ibrutinib, ruxolitinib approved for steroid-refractory cGVHD. Extracorporeal photopheresis effective. Ursodiol for liver involvement. Rituximab for steroid-refractory cases.
Affected Countries
Sources
- https://www.hematology.org
- https://www.ncbi.nlm.nih.gov/books/NBK5191
- https://www.mayoclinic.org
Medical Disclaimer
This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.